<DOC>
	<DOCNO>NCT01345708</DOCNO>
	<brief_summary>The aim prospective study evaluate activity , safety duration response low dose rituximab associate standard oral prednisone first line therapy newly diagnose warm autoimmune hemolytic anemia cold hemagglutinin disease , second line therapy warm autoimmune hemolytic anemia relapse standard oral prednisone . Further aim correlate clinical response biological parameter ( cytokine anti-erythrocyte antibody production culture ) .</brief_summary>
	<brief_title>A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Newly diagnose `` warm '' `` cold '' AIHA , define symptomatic anemia positive DAT , absence underlying lymphoproliferative , infectious neoplastic disease ( accord single Center diagnostic criterion ) . Idiopathic `` warm '' `` cold '' AIHA relapse first line treatment oral prednisone . Aged &gt; 18 year ECOG performance status grade 0 , 1 2 No psychiatric illness precludes understanding concept trial signing informed consent Patients provide write informed consent prior study participation , understanding consent may withdraw patient time without prejudice . Cell humoral immunologic deficit ( congenital acquire ) Any coexist medical psychological condition would preclude participation study compromise ability give inform consent Active bacterial , viral , fungal infection require systemic therapy HIV HbsAg positive ( HBVDNA+ ) HCVAb positive ( HCVRNA+ ) patient History malignancy within 3 year prior study entry Concomitant immunosuppressive cytotoxic treatment Positive pregnancy test . Lactation . The presence associate organspecific autoimmune disease constitute exclusion criterion . Previous splenectomy constitute exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Low dose rituximab</keyword>
	<keyword>WAIHA</keyword>
	<keyword>CHD</keyword>
</DOC>